toplogo
Sign In

New 21-Valent Pneumococcal Vaccine Approved for Adults to Prevent Invasive Disease and Pneumonia


Core Concepts
A new 21-valent pneumococcal conjugate vaccine, Capvaxive, has been approved by the FDA to protect adults against invasive pneumococcal disease and pneumococcal pneumonia.
Abstract
The content discusses the approval of a new pneumococcal vaccine, Capvaxive, by the US Food and Drug Administration. Key points: Capvaxive is a 21-valent pneumococcal conjugate vaccine that protects against 21 serotypes responsible for about 84% of invasive pneumococcal disease cases in adults aged 50+ and 85% in adults aged 65+. Pneumococcal pneumonia hospitalizes around 150,000 adults annually in the US. Capvaxive is designed to cover serotypes not included in other approved pneumococcal vaccines. Clinical testing showed Capvaxive was well-tolerated, with common side effects like pain at injection site, fatigue, headaches, and muscle aches. Capvaxive can prevent pneumonia caused by 8 serotypes not covered by other vaccines. Capvaxive is expected to compete with Pfizer's Prevnar 20, another recently approved adult pneumococcal vaccine. Capvaxive has a wholesale price of $287 per dose, but most adults will likely receive it at no cost if the CDC recommends it. A CDC advisory panel will meet on June 27 to discuss the vaccine, and the CDC director will then decide on nationwide availability.
Stats
Capvaxive protects against 21 serotypes that cause about 84% of invasive pneumococcal disease cases in adults aged 50+ and 85% in adults aged 65+. Around 150,000 adults are hospitalized annually in the US due to pneumococcal pneumonia. Capvaxive has a wholesale acquisition price of $287 per dose.
Quotes
"Many cases of adult disease are caused by serotypes not included in other approved pneumococcal conjugate vaccines. CAPVAXIVE is designed to include the serotypes that cause the majority of invasive pneumococcal disease in adults, helping to protect adults against invasive pneumococcal disease and pneumococcal pneumonia." Walter Orenstein, MD, Emory University

Deeper Inquiries

What factors will the CDC consider in their decision to recommend Capvaxive for nationwide use?

The CDC will consider several factors in their decision to recommend Capvaxive for nationwide use. These factors may include the vaccine's efficacy in preventing invasive pneumococcal disease and pneumonia, the safety profile of the vaccine based on clinical trials, the coverage of serotypes included in the vaccine, the cost-effectiveness of the vaccine compared to other available options, the burden of pneumococcal disease in the adult population, and the potential impact of widespread vaccination with Capvaxive on public health outcomes. Additionally, the CDC may also take into account recommendations from their advisory panels and expert committees, as well as feedback from healthcare providers and stakeholders.

How does the pricing and coverage of Capvaxive compare to other pneumococcal vaccines, and what impact might this have on adult vaccination rates?

Capvaxive is priced at $287 per dose, which is competitive compared to other pneumococcal vaccines in the market. However, the availability of Capvaxive at no cost to most individuals if it receives a routine CDC recommendation could significantly impact adult vaccination rates. The affordability and accessibility of the vaccine play a crucial role in determining vaccination uptake among adults. If Capvaxive is recommended for nationwide use and covered by insurance or public health programs, it is likely to increase vaccination rates among adults, especially those at higher risk of pneumococcal disease. This could lead to better protection against invasive pneumococcal disease and pneumonia in the adult population.

Given the significant burden of pneumococcal disease in adults, what other innovative approaches are being explored to further improve pneumococcal prevention and treatment?

In addition to the development of new vaccines like Capvaxive, other innovative approaches are being explored to enhance pneumococcal prevention and treatment. Some of these approaches include the use of novel vaccine technologies such as mRNA vaccines, which have shown promise in generating robust immune responses against pneumococcal infections. Furthermore, research is ongoing to identify new drug targets for antimicrobial therapy and to improve the diagnosis and management of pneumococcal infections through rapid diagnostic tests and personalized treatment strategies. Additionally, efforts are being made to strengthen surveillance systems for monitoring pneumococcal disease trends, antimicrobial resistance patterns, and vaccine effectiveness to inform public health interventions and policies. By combining these innovative approaches with vaccination strategies, it is possible to further reduce the burden of pneumococcal disease in adults and improve overall health outcomes.
0